Financings Of The Fortnight: More Celtics Than At Boston Garden
This article was originally published in The Pink Sheet Daily
Various Celtic funds were involved in quite a few financing deals over the past two weeks.
You may also be interested in...
Financing includes $1.5 million development option that converts to another Series B if there's no agreement on a co-development program.
With a broad label already in place, Amag plans to increase market for chronic kidney disease drug through label and geographic expansion.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.